[Research Progress in the Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Drugs Targeting Spike Protein].
靶向刺突蛋白的抗严重急性呼吸综合征冠状病毒2药物研究进展
📄 英文摘要 English Abstract
The coronavirus disease 2019(COVID-19) caused by severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) is spreading around the world,while the specific drugs targeting SARS-CoV-2 are still under development.On the basis of the biological characteristics of SARS-CoV-2 and the key protein(spike protein) for viral replication,this paper introduces the research progress in the action sites of related drugs,providing information for clinical application and ideas for development of anti-SARS-CoV-2 drugs.
📄 中文摘要 Chinese Abstract
📋 英文结构化总结 English Structured Summary
摘要整理
Background:
The coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is spreading around the world, while the specific drugs targeting SARS-CoV-2 are still under development.
Methods:
On the basis of the biological characteristics of SARS-CoV-2 and the key protein (spike protein) for viral replication, this paper introduces the research progress in the action sites of related drugs.
Results:
This paper introduces the research progress in the action sites of related drugs.
Data Summary:
No quantitative results or key statistics are provided in the text.
Conclusions:
Providing information for clinical application and ideas for development of anti-SARS-CoV-2 drugs.
Practical Significance:
Providing information for clinical application and ideas for development of anti-SARS-CoV-2 drugs.
📋 中文结构化总结 Chinese Structured Summary
背景:
由严重急性呼吸综合征冠状病毒2（SARS-CoV-2）引起的2019冠状病毒病（COVID-19）正在全球范围内传播，而针对SARS-CoV-2的特效药物仍在研发之中。
方法:
本文基于SARS-CoV-2的生物学特性及病毒复制的关键蛋白（刺突蛋白），介绍了相关药物作用靶点的研究进展。
结果:
本文介绍了相关药物作用靶点的研究进展。
数据摘要:
文中未提供定量结果或关键统计数据。
结论:
为临床应用提供信息，并为抗SARS-CoV-2药物的研发提供思路。
实际意义:
为临床应用提供信息，并为抗SARS-CoV-2药物的研发提供思路。